Imipramine impedes glioma progression by inhibiting YAP as a Hippo pathway independent manner and synergizes with temozolomide

Patients with malignant glioma often suffered from depression, which leads to an increased risk of detrimental outcomes. Imipramine, an FDA‐approved tricyclic antidepressant, has been commonly used to relieve depressive symptoms in the clinic. Recently, imipramine has been reported to participate in...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yan, Wang, Xiang, Wang, Xu, Wu, Di, Qi, Ji, Zhang, Yu, Wang, Kai, Zhou, Ding, Meng, Qing‐Ming, Nie, Er, Wang, Qiang, Yu, Ru‐Tong, Zhou, Xiu‐Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8500960/
https://www.ncbi.nlm.nih.gov/pubmed/34469035
http://dx.doi.org/10.1111/jcmm.16874

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8500960/
https://www.ncbi.nlm.nih.gov/pubmed/34469035
http://dx.doi.org/10.1111/jcmm.16874

Ejemplares similares